Susceptibility
of Major Pathogens - 1997
Institutional Antibiotic Control Program
Notes
Antibiotic Classes
Back to Reference Page
| Gram Positive | Gram Negative | |||||||||||||||||||
| * |
* |
|||||||||||||||||||
| Total Isolates (1997)1 | 1286 | 785 | 1224 | 384 | 1092 | 225 | 97 | 234 | 110 | 1453 | 1116 | 95 | 460 | 274 | 55 | 142 | 857 | 107 | 294 | 44 |
| Amikacin | 99 | 77 | 99 | 94 | 99 | 100 | 94 | 85 | 3 | 87 | ||||||||||
| Ampicillin | 6 | 5 | 99 | 14 | 100 | 100 | 70 | 88 | 67 | 57 | 1 | 2 | 2 | 87 | 2 | 1 | ||||
| Ampicillin/Sulbactam | 52 | 24 | 98 | 60 | 45 | 64 | 17 | 95 | 5 | 5 | ||||||||||
| Aztreonam | 98 | 58 | 92 | 56 | 98 | 91 | 77 | 63 | 2 | 18 | ||||||||||
| Cefazolin | 52 | 24 | 98 | 99 | 70 | 97 | 89 | 53 | 54 | 3 | 93 | 2 | 0 | |||||||
| Cefoxitin | 95 | 76 | 93 | 3 | 100 | 84 | 18 | 93 | ||||||||||||
| Ceftazidime | 98 | 58 | 95 | 52 | 98 | 82 | 77 | 71 | 20 | 40 | ||||||||||
| Ceftriaxone | 52 | 23 | 80 | 100 | 99 | 66 | 93 | 55 | 100 | 96 | 86 | 18 | 0 | 31 | ||||||
| Cefuroxime | 52 | 23 | 100 | 95 | 59 | 82 | 31 | 99 | 7 | 0 | ||||||||||
| Chloramphenicol | 94 | 94 | 76 | 96 | 98 | 99 | 90 | 99 | 100 | 84 | 54 | 86 | 62 | 87 | 67 | 18 | 1 | 57 | 9 | 93 |
| Ciprofloxacin | 51 | 44 | 57 | 10 | 100 | 95 | 67 | 94 | 81 | 95 | 85 | 82 | 64 | 26 | 39 | |||||
| Clindamycin | 54 | 50 | 91 | 92 | 90 | 91 | 70 | |||||||||||||
| Co-Trimoxazole3 | 85 | 50 | 75 | 87 | 78 | 61 | 94 | 77 | 92 | 78 | 86 | 4 | 95 | 40 | ||||||
| Erythromycin | 37 | 19 | 89 | 75 | 80 | 74 | ||||||||||||||
| Gentamicin | 65 | 45 | 734 | 344 | 93 | 54 | 94 | 79 | 92 | 87 | 85 | 59 | 2 | 44 | ||||||
| Imipenem/Cilastatin | 52 | 24 | 99 | 24 | 100 | 99 | 100 | 99 | 97 | 85 | 97 | 67 | 2 | 88 | ||||||
| Metronidazole | 100 | |||||||||||||||||||
| Nafcillin | 52 | 24 | ||||||||||||||||||
| Penicillin | 6 | 5 | 100 | 100 | 70 | 88 | 7 | |||||||||||||
| Piperacillin | 86 | |||||||||||||||||||
| Piperacillin/Tazobactam | 94 | 61 | 89 | 65 | 100 | 96 | 92 | 72 | 33 | 69 | 865 | |||||||||
| Sulfonamide (urine) | 64 | 60 | 73 | 64 | 89 | 70 | 85 | 100 | 46 | |||||||||||
| Tetracycline | 32 | 63 | 75 | 13 | 84 | 7 | ||||||||||||||
| Ticarcillin/Clavulanate | 52 | 24 | 87 | 55 | 87 | 47 | 99 | 89 | 79 | 62 | 36 | 43 | 91 | |||||||
| Tobramycin | 95 | 54 | 95 | 81 | 93 | 87 | 81 | 76 | 2 | 83 | ||||||||||
| Vancomycin | 100 | 1006 | 95 | 24 | 100 | 100 | 100 | 100 | ||||||||||||
1. Percent susceptibility
includes duplicate isolates from same patient.
2. Includes both inpatients and outpatients.
3. Co-Trimoxazole is Sulfamethoxazole plus Trimethoprim.
4. Gentamicin synergy.
5. Tested against piperacillln; actual percent susceptible isolates may be higher
for piperacillin / tazobactam.
6. Intermediate resistant isolates recovered from one ambulatory patient.
| Approved by: | The Subcommittee on Antibiotic Use Committee on Infections Medical Board |
March 1998 |
Antibiotic
Classes
Back to Reference Page
Page created with permission: October 14, 1998
Created: October
14, 1998
Edited: October
3, 2000.
Copyright © 1998-2001.